Skip to content
10-Q

Quarterly Report

SUPERNUS PHARMACEUTICALS, INC. SUPN

0001356576-26-000022

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 28, 2026 58.04M sh
Shares Diluted Q1 2026 · Mar 31, 2026 57.65M sh
Shares Diluted Q1 2026 · Mar 31, 2025 55.86M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $327K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $66.52M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $30.6M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $184.87M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $128.45M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $115.85M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.08B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.06B
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.03B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.04B
Current Liabilities Q1 2026 · Mar 31, 2026 $373.93M
Current Liabilities Q1 2026 · Dec 31, 2025 $338.17M
Total Liabilities Q1 2026 · Mar 31, 2026 $423.92M
Total Liabilities Q1 2026 · Dec 31, 2025 $390.93M
Current Assets Q1 2026 · Mar 31, 2026 $731.58M
Current Assets Q1 2026 · Dec 31, 2025 $644.18M
Total Assets Q1 2026 · Mar 31, 2026 $1.5B
Total Assets Q1 2026 · Dec 31, 2025 $1.45B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.04
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.21
Eps Basic Q1 2026 · Mar 31, 2026 −$0.04
Eps Basic Q1 2026 · Mar 31, 2025 −$0.21
Sga Expense Q1 2026 · Mar 31, 2026 $125.17M
Sga Expense Q1 2026 · Mar 31, 2025 $89.94M
Rd Expense Q1 2026 · Mar 31, 2026 $39.44M
Rd Expense Q1 2026 · Mar 31, 2025 $26.93M
Net Income Q1 2026 · Mar 31, 2026 −$2.29M
Net Income Q1 2026 · Mar 31, 2025 −$11.83M
Operating Income Q1 2026 · Mar 31, 2026 −$8.33M
Operating Income Q1 2026 · Mar 31, 2025 −$10.26M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $23.39M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $15.76M
Revenue Q1 2026 · Mar 31, 2026 $207.71M
Revenue Q1 2026 · Mar 31, 2025 $149.82M